EP1178829A4 - Anticorps monoclonal humain - Google Patents

Anticorps monoclonal humain

Info

Publication number
EP1178829A4
EP1178829A4 EP00939304A EP00939304A EP1178829A4 EP 1178829 A4 EP1178829 A4 EP 1178829A4 EP 00939304 A EP00939304 A EP 00939304A EP 00939304 A EP00939304 A EP 00939304A EP 1178829 A4 EP1178829 A4 EP 1178829A4
Authority
EP
European Patent Office
Prior art keywords
monoclonal antibody
human monoclonal
human
antibody
monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00939304A
Other languages
German (de)
English (en)
Other versions
EP1178829A1 (fr
Inventor
Mitchell S Gross
Raymond W Sweet
Geraldine Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1178829A1 publication Critical patent/EP1178829A1/fr
Publication of EP1178829A4 publication Critical patent/EP1178829A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP00939304A 1999-05-18 2000-05-18 Anticorps monoclonal humain Withdrawn EP1178829A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13470299P 1999-05-18 1999-05-18
US134702P 1999-05-18
PCT/US2000/013694 WO2000069462A1 (fr) 1999-05-18 2000-05-18 Anticorps monoclonal humain

Publications (2)

Publication Number Publication Date
EP1178829A1 EP1178829A1 (fr) 2002-02-13
EP1178829A4 true EP1178829A4 (fr) 2005-06-08

Family

ID=22464579

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00939304A Withdrawn EP1178829A4 (fr) 1999-05-18 2000-05-18 Anticorps monoclonal humain

Country Status (6)

Country Link
EP (1) EP1178829A4 (fr)
JP (1) JP2002543822A (fr)
AR (1) AR030019A1 (fr)
AU (1) AU5441000A (fr)
CO (1) CO5280147A1 (fr)
WO (1) WO2000069462A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
WO2006106905A1 (fr) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d’un ensemble
CA2611726C (fr) * 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique contenant sc(fv)2
CA2610987C (fr) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilisant pour une preparation de proteine contenant de la meglumine et son utilisation
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
NZ597314A (en) 2009-06-05 2013-07-26 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2507262A1 (fr) 2009-11-30 2012-10-10 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire
TWI659968B (zh) * 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EP3398965A4 (fr) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour favoriser l'efficacité de purification d'un polypeptide contenant une région fc

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006448A1 (fr) * 1992-09-16 1994-03-31 The Scripps Research Institute Anticorps monoclonaux neutralisateurs humains contre le virus respiratoire syncytial
WO1998019704A1 (fr) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Anticorps monoclonaux humains

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006448A1 (fr) * 1992-09-16 1994-03-31 The Scripps Research Institute Anticorps monoclonaux neutralisateurs humains contre le virus respiratoire syncytial
WO1998019704A1 (fr) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Anticorps monoclonaux humains

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0069462A1 *

Also Published As

Publication number Publication date
AR030019A1 (es) 2003-08-13
JP2002543822A (ja) 2002-12-24
AU5441000A (en) 2000-12-05
EP1178829A1 (fr) 2002-02-13
CO5280147A1 (es) 2003-05-30
WO2000069462A1 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
AU1462300A (en) Human pan-hcv human monoclonal antibodies
IL136335A0 (en) Monoclonal human natural antibodies
IL156030A0 (en) Humanized antibodies
GB9809839D0 (en) Antibody
EE200000470A (et) Inimese CD40-vastased antikehad
AU1174702A (en) Humanized anti-lt-beta-r antibodies
GB9911569D0 (en) Antibodies
EP1071458A4 (fr) Anticorps humanises et utilisations correspondantes
HUP0104604A3 (en) Human monoclonal antibodies to ctla-4
GB0029360D0 (en) Humanised antibodies and uses thereof
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
EP1178829A4 (fr) Anticorps monoclonal humain
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
IL206565A0 (en) An antibody immunospecific for an igs4 polypeptide
HUP9800613A3 (en) Humanized antibody against human fas-antigene
EP0977590A4 (fr) Anticorps monoclonaux humains
GB9818915D0 (en) Antibodies
GB9828700D0 (en) Antibody
GB9718911D0 (en) Monoclonal antibodies
GB9819411D0 (en) Antibodies
GB9915419D0 (en) Antigens
GB9825184D0 (en) Antigen
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
GB9927698D0 (en) Therapeutic antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050421

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060719